Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice

NCT01782690 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01782690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01782690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
March 31, 2012
Completion date
February 28, 2015
Enrollment
338 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer